Elisha D. O. Roberson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Elisha D. O. Roberson has a total of 319 co-authors. Here are the top co-authors by number of shared publications:
Li Cao
Department of Medicine, Division of Rheumatology, Washington University, St. Louis, MO, USA
11 shared publications- Anne M. Bowcock
Icahn School of Medicine at Mount Sinai, New York, New York
7 shared publications - Jonathan Pevsner
Department of Neurology, Kennedy Krieger Institute, Baltimore, MD, USA
6 shared publications Rosana A. Mesa
Department of Medicine
4 shared publicationsShenghui Duan
Division of Human Genetics, Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA
4 shared publicationsAlan Menter
Psoriasis Research Institute, Baylor University Medical Center, Dallas, TX 75246, USA
3 shared publications
Latest Publications
- Open Access
The small genomics lab experience optimizing data cold storage
Translational research is often a collaborative enterprise that involves basic science researchers, clinicians, and experts in genomics and bioinformatics. While there are central university and industry cores to support data generation, long-term storage often falls to the individual investigators. We frequently fulfill the role of long-term FASTQ file storage for our collaborators. To reduce our cold storage space, we tested the space savings for gzip and zstandard algorithms on an old set of FASTQ files. We found that zstandard had a better overall compression ratio than the best gzip algorithm, amounting to more than 20% space savings overall compared to gzip. It may be worth transitioning to zstandard compression for small, collaborative genomics labs to minimize cold storage costs.
Open AccessThe small genomics lab experience optimizing data cold storage
Translational research is often a collaborative enterprise that involves basic science researchers, clinicians, and experts in genomics and bioinformatics. While there are central university and industry cores to support data generation, long-term storage often falls to the individual investigators. We frequently fulfill the role of long-term FASTQ file storage for our collaborators. To reduce our cold storage space, we tested the space savings for gzip and zstandard algorithms on an old set of FASTQ files. We found that zstandard had a better overall compression ratio than the best gzip algorithm, amounting to more than 20% space savings overall compared to gzip. It may be worth transitioning to zstandard compression for small, collaborative genomics labs to minimize cold storage costs.
- Top Cited PapersOpen Access
- 18 July 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (16)
Mucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis
HLA-B*27 was one of the first HLA alleles associated with an autoimmune disease, i.e., axial spondyloarthritis (axSpA) and acute anterior uveitis (B27AAU), which cause joint and eye inflammation, respectively. Gastrointestinal inflammation has been suggested as a trigger of axSpA. We recently identified a bacterial peptide (YeiH) that can be presented by HLA-B*27 to expanded public T cell receptors in the joint in axSpA and the eye in B27AAU. While YeiH is present in enteric microbiota and pathogens, additional evidence that pathogenic T cells in HLA-B*27–associated autoimmunity may have had a prior antigenic encounter within the gastrointestinal tract remains lacking. Here, we analyzed ocular, synovial, and blood T cells in B27AAU and axSpA, showing that YeiH-specific CD8 + T cells express a mucosal gene set and surface proteins consistent with intestinal differentiation, including CD161, integrin α4β7, and CCR6. In addition, we found an expansion of YeiH-specific CD8 + T cells in axSpA and B27AAU blood compared with that from individuals acting as healthy controls, whereas influenza-specific CD8 + T cells were equivalent across groups. Finally, we demonstrated the dispensability of TRBV9 for antigen recognition. Collectively, our data suggest that, in HLA-B27–associated autoimmunity, early antigen exposure and differentiation of pathogenic CD8 + T cells may occur in enteric organs.
- 18 July 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (16)
Top Cited PapersOpen AccessMucosal signatures of pathogenic T cells in HLA-B*27+ anterior uveitis and axial spondyloarthritis
HLA-B*27 was one of the first HLA alleles associated with an autoimmune disease, i.e., axial spondyloarthritis (axSpA) and acute anterior uveitis (B27AAU), which cause joint and eye inflammation, respectively. Gastrointestinal inflammation has been suggested as a trigger of axSpA. We recently identified a bacterial peptide (YeiH) that can be presented by HLA-B*27 to expanded public T cell receptors in the joint in axSpA and the eye in B27AAU. While YeiH is present in enteric microbiota and pathogens, additional evidence that pathogenic T cells in HLA-B*27–associated autoimmunity may have had a prior antigenic encounter within the gastrointestinal tract remains lacking. Here, we analyzed ocular, synovial, and blood T cells in B27AAU and axSpA, showing that YeiH-specific CD8 + T cells express a mucosal gene set and surface proteins consistent with intestinal differentiation, including CD161, integrin α4β7, and CCR6. In addition, we found an expansion of YeiH-specific CD8 + T cells in axSpA and B27AAU blood compared with that from individuals acting as healthy controls, whereas influenza-specific CD8 + T cells were equivalent across groups. Finally, we demonstrated the dispensability of TRBV9 for antigen recognition. Collectively, our data suggest that, in HLA-B27–associated autoimmunity, early antigen exposure and differentiation of pathogenic CD8 + T cells may occur in enteric organs.
- Open Access
Systemic delivery of murine SOD2 mRNA to experimental abdominal aortic aneurysm mitigates expansion and rupture
Background: Oxidative stress is implicated in the pathogenesis and progression of abdominal aortic aneurysm (AAA). Antioxidant delivery as a therapeutic for AAA is of substantial interest although clinical translation of antioxidant therapy has met with significant challenges due to limitations in achieving sufficient antioxidant levels at the site of AAA. We posit that nanoparticle-based approaches hold promise to overcome challenges associated with systemic administration of antioxidants. Methods: We employed a peptide-based nanoplatform to overexpress a key modulator of oxidative stress, superoxide dismutase 2 (SOD2). The efficacy of systemic delivery of SOD2 mRNA as a nanotherapeutic agent was studied in two different murine AAA models. Unbiased mass spectrometry-enabled proteomics and high-dimensional bioinformatics were used to examine pathways modulated by SOD2 overexpression. Results: The murine SOD2 mRNA sequence was mixed with p5RHH, an amphipathic peptide capable of delivering nucleic acids in vivo to form self-assembled nanoparticles of ∼55 nm in diameter. We further demonstrated that the nanoparticle was stable and functional up to four weeks following self-assembly when coated with hyaluronic acid. Delivery of SOD2 mRNA mitigated the expansion of small AAA and largely prevented rupture. Mitigation of AAA was accompanied by enhanced SOD2 protein expression in aortic wall tissue. Concomitant suppression of nitric oxide, inducible nitric oxide synthase expression, and cell death was observed. Proteomic profiling of AAA tissues suggests that SOD2 overexpression augments levels of microRNAs that regulate vascular inflammation and cell apoptosis, inhibits platelet activation/aggregation, and downregulates mitogen-activated protein kinase signaling. Gene set enrichment analysis shows that SOD2 mRNA delivery is associated with activation of oxidative phosphorylation, lipid metabolism, respiratory electron transportation, and tricarboxylic acid cycle pathways. Conclusions: These results confirm that SOD2 is key modulator of oxidative stress in AAA. This nanotherapeutic mRNA delivery approach may find translational application in the medical management of small AAA and the prevention of AAA rupture.
Open AccessSystemic delivery of murine SOD2 mRNA to experimental abdominal aortic aneurysm mitigates expansion and rupture
Background: Oxidative stress is implicated in the pathogenesis and progression of abdominal aortic aneurysm (AAA). Antioxidant delivery as a therapeutic for AAA is of substantial interest although clinical translation of antioxidant therapy has met with significant challenges due to limitations in achieving sufficient antioxidant levels at the site of AAA. We posit that nanoparticle-based approaches hold promise to overcome challenges associated with systemic administration of antioxidants. Methods: We employed a peptide-based nanoplatform to overexpress a key modulator of oxidative stress, superoxide dismutase 2 (SOD2). The efficacy of systemic delivery of SOD2 mRNA as a nanotherapeutic agent was studied in two different murine AAA models. Unbiased mass spectrometry-enabled proteomics and high-dimensional bioinformatics were used to examine pathways modulated by SOD2 overexpression. Results: The murine SOD2 mRNA sequence was mixed with p5RHH, an amphipathic peptide capable of delivering nucleic acids in vivo to form self-assembled nanoparticles of ∼55 nm in diameter. We further demonstrated that the nanoparticle was stable and functional up to four weeks following self-assembly when coated with hyaluronic acid. Delivery of SOD2 mRNA mitigated the expansion of small AAA and largely prevented rupture. Mitigation of AAA was accompanied by enhanced SOD2 protein expression in aortic wall tissue. Concomitant suppression of nitric oxide, inducible nitric oxide synthase expression, and cell death was observed. Proteomic profiling of AAA tissues suggests that SOD2 overexpression augments levels of microRNAs that regulate vascular inflammation and cell apoptosis, inhibits platelet activation/aggregation, and downregulates mitogen-activated protein kinase signaling. Gene set enrichment analysis shows that SOD2 mRNA delivery is associated with activation of oxidative phosphorylation, lipid metabolism, respiratory electron transportation, and tricarboxylic acid cycle pathways. Conclusions: These results confirm that SOD2 is key modulator of oxidative stress in AAA. This nanotherapeutic mRNA delivery approach may find translational application in the medical management of small AAA and the prevention of AAA rupture.
- Top Cited PapersOpen Access
- 10 April 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (5) , 875-888
Uropathogenic Escherichia coli infection-induced epithelial trained immunity impacts urinary tract disease outcome
Previous urinary tract infections (UTIs) can predispose one to future infections; however, the underlying mechanisms affecting recurrence are poorly understood. We previously found that UTIs in mice cause differential bladder epithelial (urothelial) remodelling, depending on disease outcome, that impacts susceptibility to recurrent UTI. Here we compared urothelial stem cell (USC) lines isolated from mice with a history of either resolved or chronic uropathogenic Escherichia coli (UPEC) infection, elucidating evidence of molecular imprinting that involved epigenetic changes, including differences in chromatin accessibility, DNA methylation and histone modification. Epigenetic marks in USCs from chronically infected mice enhanced caspase-1-mediated cell death upon UPEC infection, promoting bacterial clearance. Increased Ptgs2os2 expression also occurred, potentially contributing to sustained cyclooxygenase-2 expression, bladder inflammation and mucosal wounding—responses associated with severe recurrent cystitis. Thus, UPEC infection acts as an epi-mutagen reprogramming the urothelial epigenome, leading to urothelial-intrinsic remodelling and training of the innate response to subsequent infection.
- 10 April 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (5) , 875-888
Top Cited PapersOpen AccessUropathogenic Escherichia coli infection-induced epithelial trained immunity impacts urinary tract disease outcome
Previous urinary tract infections (UTIs) can predispose one to future infections; however, the underlying mechanisms affecting recurrence are poorly understood. We previously found that UTIs in mice cause differential bladder epithelial (urothelial) remodelling, depending on disease outcome, that impacts susceptibility to recurrent UTI. Here we compared urothelial stem cell (USC) lines isolated from mice with a history of either resolved or chronic uropathogenic Escherichia coli (UPEC) infection, elucidating evidence of molecular imprinting that involved epigenetic changes, including differences in chromatin accessibility, DNA methylation and histone modification. Epigenetic marks in USCs from chronically infected mice enhanced caspase-1-mediated cell death upon UPEC infection, promoting bacterial clearance. Increased Ptgs2os2 expression also occurred, potentially contributing to sustained cyclooxygenase-2 expression, bladder inflammation and mucosal wounding—responses associated with severe recurrent cystitis. Thus, UPEC infection acts as an epi-mutagen reprogramming the urothelial epigenome, leading to urothelial-intrinsic remodelling and training of the innate response to subsequent infection.
- Open Access
- 13 March 2023
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 4 (2) , 100187
Rare missense variants in the SH3 domain of PSTPIP1 are associated with hidradenitis suppurativa
- 13 March 2023
- Published by Elsevier in Human Genetics and Genomics Advances
- Vol. 4 (2) , 100187
Open AccessRare missense variants in the SH3 domain of PSTPIP1 are associated with hidradenitis suppurativa
- 29 November 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (1) , 108-119
Alterations of the Primary Cilia Gene SPAG17 and SOX9 Locus Noncoding RNAs Identified by RNA‐Sequencing Analysis in Patients With Systemic Sclerosis
Objective: Systemic sclerosis (SSc) is characterized by immune activation, vasculopathy, and unresolving fibrosis in the skin, lungs, and other organs. We performed RNA‐sequencing analysis on skin biopsy samples and peripheral blood mononuclear cells (PBMCs) from SSc patients and unaffected controls to better understand the pathogenesis of SSc.Methods: We analyzed these data 1) to test for case/control differences and 2) to identify genes whose expression levels correlate with SSc severity as measured by local skin score, modified Rodnan skin thickness score (MRSS), forced vital capacity (FVC), or diffusing capacity for carbon monoxide (DLco).Results: We found that PBMCs from SSc patients showed a strong type I interferon signature. This signal was found to be replicated in the skin, with additional signals for increased extracellular matrix (ECM) genes, classical complement pathway activation, and the presence of B cells. Notably, we observed a marked decrease in the expression of SPAG17, a cilia component, in SSc skin. We identified genes that correlated with the MRSS, DLco, and FVC in SSc PBMCs and skin using weighted gene coexpression network analysis. These genes were largely distinct from the case/control differentially expressed genes. In PBMCs, type I interferon signatures negatively correlated with the DLco. In SSc skin, ECM gene expression positively correlated with the MRSS. Network analysis of SSc skin genes that correlated with clinical features identified the noncoding RNAs SOX9‐AS1 and ROCR, both near the SOX9 locus, as highly connected, “hub‐like” genes in the network.Conclusion: These results identify noncoding RNAs and SPAG17 as novel factors potentially implicated in the pathogenesis of SSc.
- 29 November 2022
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (1) , 108-119
Alterations of the Primary Cilia Gene SPAG17 and SOX9 Locus Noncoding RNAs Identified by RNA‐Sequencing Analysis in Patients With Systemic Sclerosis
Objective: Systemic sclerosis (SSc) is characterized by immune activation, vasculopathy, and unresolving fibrosis in the skin, lungs, and other organs. We performed RNA‐sequencing analysis on skin biopsy samples and peripheral blood mononuclear cells (PBMCs) from SSc patients and unaffected controls to better understand the pathogenesis of SSc.Methods: We analyzed these data 1) to test for case/control differences and 2) to identify genes whose expression levels correlate with SSc severity as measured by local skin score, modified Rodnan skin thickness score (MRSS), forced vital capacity (FVC), or diffusing capacity for carbon monoxide (DLco).Results: We found that PBMCs from SSc patients showed a strong type I interferon signature. This signal was found to be replicated in the skin, with additional signals for increased extracellular matrix (ECM) genes, classical complement pathway activation, and the presence of B cells. Notably, we observed a marked decrease in the expression of SPAG17, a cilia component, in SSc skin. We identified genes that correlated with the MRSS, DLco, and FVC in SSc PBMCs and skin using weighted gene coexpression network analysis. These genes were largely distinct from the case/control differentially expressed genes. In PBMCs, type I interferon signatures negatively correlated with the DLco. In SSc skin, ECM gene expression positively correlated with the MRSS. Network analysis of SSc skin genes that correlated with clinical features identified the noncoding RNAs SOX9‐AS1 and ROCR, both near the SOX9 locus, as highly connected, “hub‐like” genes in the network.Conclusion: These results identify noncoding RNAs and SPAG17 as novel factors potentially implicated in the pathogenesis of SSc.
- Open Access
Inhibition of extracellular vesicle-encapsulated miRNA produced by estrogen-mediated upregulation of cellular processing suppresses target organ inflammation in a humanized model of systemic lupus erythematosus
Background/Purpose Distinct, disease-associated intracellular miRNA (miR) expression profiles have been identified from peripheral blood mononuclear cells (PBMCs) of systemic lupus erythematous (SLE) patients. We have previously demonstrated novel estrogenic responses in PBMCs from SLE patients and discovered that estrogen lowers the threshold of immune cell activation to a greater extent in females, including significant upregulation of toll-like receptor (TLR)7 and TLR8 expression. TLR7 and TLR8 bind viral-derived single-stranded RNA to stimulate innate inflammatory responses, but recent studies have shown that miR-21, mir-29a, and miR-29b can also bind and activate these receptors when packaged and secreted in extracellular vesicles (EVs). Objective The objective of this study was to characterize the estrogen-mediated immunomodulatory effects of distinct EV-encapsulated miR profiles in SLE and evaluate the potential therapeutic approach of miR inhibition in a humanized mouse model. Methods SLE patients meeting revised ACR guidelines and age/sex-matched healthy controls provided informed consent to participate in this IRB-approved study. Plasma-derived EVs were isolated by differential ultracentrifugation and quantified. PBMCs were isolated from whole blood and cultured in hormone free conditions before stimulation with 17β-estradiol (estrogen; E2). RNA was isolated following E2 stimulation or EV isolation and bulk RNA-sequencing (RNAseq) reads were analyzed. Additionally, PBMCs from active SLE patients were injected into immunodeficient mice to produce chimeras. Prior to transfer, the PBMCs were incubated with liposomal EVs containing complementary locked nucleic acid (LNA) antagonists to miR-21, mir-29a, and miR-29b. After three weeks, blood was collected for both immunophenotyping and cytokine analysis and tissue was harvested for histopathological examination. Results EVs were found to be increased in the plasma of SLE patients and differentially expressed EV-derived miR profiles were detected compared to healthy controls, including miR-21, mir-29a, and miR-29b. E2 stimulation of PBMCs identified upregulated pathways involved in miR transcription/processing. Specifically, small RNA binding proteins and synthesis enzymes demonstrated significant signaling pathway association and upregulation with E2 treatment. Human immune cell subtypes were successfully recovered from whole blood of chimeric mice at similar levels with and without miR inhibition, but levels of human IL-6, IL-1β, IL-4, and TNF-α were significantly reduced by the LNA antagonists. Moreover, miR antagonists significantly reduced histopathological infiltrates in the small intestine, liver, and kidney, as demonstrated by H&E-stained tissue sections and immunohistochemistry measuring human CD3. Conclusion These data suggest E2-mediated regulation of miR synthesis and demonstrate distinct EV-derived small RNA signatures representing SLE-associated biomarkers. Targeting upregulated EV-encapsulated miR signaling by antagonizing miRs that may bind to TLR7 and TLR8 reveals a novel therapeutic opportunity to suppress autoimmune-mediated inflammation and pathogenesis in SLE.
Open AccessInhibition of extracellular vesicle-encapsulated miRNA produced by estrogen-mediated upregulation of cellular processing suppresses target organ inflammation in a humanized model of systemic lupus erythematosus
Background/Purpose Distinct, disease-associated intracellular miRNA (miR) expression profiles have been identified from peripheral blood mononuclear cells (PBMCs) of systemic lupus erythematous (SLE) patients. We have previously demonstrated novel estrogenic responses in PBMCs from SLE patients and discovered that estrogen lowers the threshold of immune cell activation to a greater extent in females, including significant upregulation of toll-like receptor (TLR)7 and TLR8 expression. TLR7 and TLR8 bind viral-derived single-stranded RNA to stimulate innate inflammatory responses, but recent studies have shown that miR-21, mir-29a, and miR-29b can also bind and activate these receptors when packaged and secreted in extracellular vesicles (EVs). Objective The objective of this study was to characterize the estrogen-mediated immunomodulatory effects of distinct EV-encapsulated miR profiles in SLE and evaluate the potential therapeutic approach of miR inhibition in a humanized mouse model. Methods SLE patients meeting revised ACR guidelines and age/sex-matched healthy controls provided informed consent to participate in this IRB-approved study. Plasma-derived EVs were isolated by differential ultracentrifugation and quantified. PBMCs were isolated from whole blood and cultured in hormone free conditions before stimulation with 17β-estradiol (estrogen; E2). RNA was isolated following E2 stimulation or EV isolation and bulk RNA-sequencing (RNAseq) reads were analyzed. Additionally, PBMCs from active SLE patients were injected into immunodeficient mice to produce chimeras. Prior to transfer, the PBMCs were incubated with liposomal EVs containing complementary locked nucleic acid (LNA) antagonists to miR-21, mir-29a, and miR-29b. After three weeks, blood was collected for both immunophenotyping and cytokine analysis and tissue was harvested for histopathological examination. Results EVs were found to be increased in the plasma of SLE patients and differentially expressed EV-derived miR profiles were detected compared to healthy controls, including miR-21, mir-29a, and miR-29b. E2 stimulation of PBMCs identified upregulated pathways involved in miR transcription/processing. Specifically, small RNA binding proteins and synthesis enzymes demonstrated significant signaling pathway association and upregulation with E2 treatment. Human immune cell subtypes were successfully recovered from whole blood of chimeric mice at similar levels with and without miR inhibition, but levels of human IL-6, IL-1β, IL-4, and TNF-α were significantly reduced by the LNA antagonists. Moreover, miR antagonists significantly reduced histopathological infiltrates in the small intestine, liver, and kidney, as demonstrated by H&E-stained tissue sections and immunohistochemistry measuring human CD3. Conclusion These data suggest E2-mediated regulation of miR synthesis and demonstrate distinct EV-derived small RNA signatures representing SLE-associated biomarkers. Targeting upregulated EV-encapsulated miR signaling by antagonizing miRs that may bind to TLR7 and TLR8 reveals a novel therapeutic opportunity to suppress autoimmune-mediated inflammation and pathogenesis in SLE.
- 15 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 284-293
Reduced SPAG17 Expression in Systemic Sclerosis Triggers Myofibroblast Transition and Drives Fibrosis
- 15 September 2022
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (2) , 284-293
Reduced SPAG17 Expression in Systemic Sclerosis Triggers Myofibroblast Transition and Drives Fibrosis
- Open Access
Rare missense variants in the SH3 domain of PSTPIP1 are associated with hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease estimated to affect ∼1% of the population, for which few treatment options are available. Risk factors associated with HS include smoking, obesity, and some high penetrance genetic variants. Some rare families have autosomal dominant inheritance. Previous studies have shown that rare loss-of-function variants in genes of the gamma-secretase complex, particularly nicastrin , segregate with autosomal dominant HS in some kindred. However, these gamma-secretase variants do not explain much of the overall genetic risk for HS. We performed targeted DNA sequencing of 21 candidate genes in a cohort of 117 individuals with HS to test for an increased burden of rare genetic variants. Candidates included the genes of the gamma-secretase complex, Notch signaling genes, and PSTPIP1 , a known risk factor for PAPA syndrome. We discovered two pathogenic loss-of-function variants in nicastrin that to the best of our knowledge have not been described in HS before. We did not identify significant enrichment of rare missense variants in any gamma-secretase gene, further supporting that loss-of-function in gamma-secretase genes is not a common risk factor. We did, however, identify a statistically significant enrichment of rare variants in the SH3 domain of PSTPIP1 . Clinical overlap between HS and PSTPIP1 syndromic features has been noted clinically. Our data suggest that there is shared genetic risk as well, and highlights the need for further population-scale HS genetic research.
Open AccessRare missense variants in the SH3 domain of PSTPIP1 are associated with hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease estimated to affect ∼1% of the population, for which few treatment options are available. Risk factors associated with HS include smoking, obesity, and some high penetrance genetic variants. Some rare families have autosomal dominant inheritance. Previous studies have shown that rare loss-of-function variants in genes of the gamma-secretase complex, particularly nicastrin , segregate with autosomal dominant HS in some kindred. However, these gamma-secretase variants do not explain much of the overall genetic risk for HS. We performed targeted DNA sequencing of 21 candidate genes in a cohort of 117 individuals with HS to test for an increased burden of rare genetic variants. Candidates included the genes of the gamma-secretase complex, Notch signaling genes, and PSTPIP1 , a known risk factor for PAPA syndrome. We discovered two pathogenic loss-of-function variants in nicastrin that to the best of our knowledge have not been described in HS before. We did not identify significant enrichment of rare missense variants in any gamma-secretase gene, further supporting that loss-of-function in gamma-secretase genes is not a common risk factor. We did, however, identify a statistically significant enrichment of rare variants in the SH3 domain of PSTPIP1 . Clinical overlap between HS and PSTPIP1 syndromic features has been noted clinically. Our data suggest that there is shared genetic risk as well, and highlights the need for further population-scale HS genetic research.
- 4 June 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (9) , 1445-1447
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy
- 4 June 2022
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (9) , 1445-1447
C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy